A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
CompletedOBSERVATIONAL
Enrollment
192
Participants
Timeline
Start Date
July 31, 2006
Primary Completion Date
August 31, 2009
Study Completion Date
August 31, 2009
Conditions
Multiple Sclerosis, Relapsing-Remitting
All Listed Sponsors
lead
Merck KGaA, Darmstadt, Germany
INDUSTRY
NCT01142583 - A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis | Biotech Hunter | Biotech Hunter